After failure, Zynerba shifts gears to save cash
Zynerba Pharmaceuticals on Thursday announced negative topline results from a Phase 1 safety and dosing study of its transdermal tetrahydrocannabinol…
Zynerba Pharmaceuticals on Thursday announced negative topline results from a Phase 1 safety and dosing study of its transdermal tetrahydrocannabinol…